mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer

This study is a prospective, single-arm, multicenter, phase Ib/II clinical trial that treats previously untreated patients with locally advanced or metastatic pancreatic cancer using mFOLFIRINOX in combination with anlotinib and sintilimab. The purpose of this trial is to evaluate the efficacy and safety of this treatment regimen and to preliminarily explore the correlation between biomarkers and treatment outcomes.

NCT Number	NCT06761027
Lead Sponsor	Fujian Provincial Hospital
Conditions	Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer
Enrollment	29 participants
Start Date	2024-12-23
Primary Completion	2027-03 (estimated)
Study Completion	2027-05 (estimated)
Updated on ClinicalTrials.gov	2025-01-07